Xaira Therapeutics

South San Francisco, United States · Founded 2023

Employees
51–200
Founded
2023
Business Model
B2B
Website
xaira.com
Last Round
Series AApr 2024
Rounds
1

About

Xaira Therapeutics is an integrated biotechnology company that brings together advanced AI research, expansive data generation, and robust therapeutic product development to transform drug discovery. Co-founded and incubated by ARCH Venture Partners and Foresite Labs, Xaira's computational core is built on foundational work by Nobel Laureate Dr. David Baker and his team at the Institute for Protein Design at the University of Washington, leveraging AI to design entirely new proteins from scratch. The company develops AI capabilities ranging from fundamental computational methods to molecule design and clinical development, underpinned by a robust data platform generating multidimensional datasets spanning molecular to human scales. In 2026, the company launched X-Cell, its first virtual cell model trained on the largest-ever genome-wide perturbation dataset, with software and model weights released on GitHub.

Summary

Xaira Therapeutics is an Artificial Intelligence company based in South San Francisco, United States, founded in 2023. Its most recent funding was a Series A round in Apr 2024.

Tech & App Stack

3 technologies & apps tracked

Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.

Sign up to view the funding chart

Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.

Funding History

Series AApr 2024

Similar Companies